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ABSTRACT 1 
Purpose This study determined whether calcium co-ingestion potentiates postprandial GIP1-42 and GLP-1 2 
concentrations in humans, and the concomitant impact on insulin, appetite sensations and substrate 3 
metabolism.  4 
Methods Ten healthy males consumed two energy- and macronutrient-matched meals in a double-blind, 5 
randomized, crossover design. The calcium content of the control meal was 3 mg/kg body mass, which 6 
was increased to 15 mg/kg body mass with calcium co-ingestion. Circulating concentrations of GIP1-42, 7 
GLP-1 and insulin were determined over a 180-min postprandial period, followed by 60 min of exercise. 8 
Visual analogue scales were used to determine subjective appetite sensations. Rates of energy 9 
expenditure and substrate (lipid and carbohydrate) oxidation were estimated using indirect calorimetry.  10 
Results Calcium co-ingestion resulted in a 47% increase in GIP1-42, a 22% increase in GLP-1 and a 19% 11 
increase in insulin areas under the curve for the 120 min following consumption (all P < 0.05). 12 
Furthermore, appetite sensations were suppressed by calcium co-ingestion by 12% (P = 0.034). No 13 
differences, however, were observed in substrate metabolism (P > 0.05).  14 
Conclusion Ingestion of a high-calcium meal potentiates postprandial GIP1-42, GLP-1 and insulin 15 
concentrations in humans. Subjective appetite is also temporarily suppressed, although substrate 16 
metabolism is unaffected. 17 
 18 
Keywords: Dairy, GIP, GLP-1, Incretin, Appetite, Lipid oxidation, Exercise 19 
 20 
Abbreviations: GIP, glucose-dependent insulinotropic peptide; GLP-1, glucagon-like peptide 1; DPP-IV, 21 
dipetidyl-peptidase IV; NEFA, non-esterified fatty acid; VAS, 22 
visual analogue scale; CHO, carbohydrate; CON, control trial; CAL, 23 
high-calcium trial; AUC, area under the curve; RER, respiratory 24 
exchange ratio; VO2, rate of oxygen consumption; VCO2, rate of 25 
carbon dioxide production. 26 
 27 
 28 
INTRODUCTION 29 
Habitual calcium intake is inversely associated with obesity[1] and type 2 diabetes[2], and calcium and 30 
vitamin D supplementation can augment fat loss under energy restriction[3]. Currently, potential explanations 31 
for the protective effect of higher-calcium intake include, improvements in appetite regulation[4], increases in 32 
lipid oxidation[5] (which may be greater during exercise/energy deficit[6]) and/or reductions in dietary fat 33 
absorption[7]. 34 
Of these putative mechanisms, the least well studied is that of calcium intake and appetite. Some have 35 
shown a reduction in 24-h energy intake following a high-calcium meal [4], whilst others have found no 36 
difference in energy intake, appetite ratings, or postprandial concentrations of appetite-related hormones such as 37 
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insulin and glucagon-like peptide-1 (GLP-1)[8]. 38 
Following food consumption, the gastrointestinal peptides, glucose-dependent insulinotropic peptide1-42 39 
(GIP1-42) and glucagon-like peptide-17-36 (GLP-17-36), are secreted by K-cells and L-cells of the intestine [for a 40 
review see Holst[9]]. These peptides potentiate insulin secretion by direct action on β-cells[10,11], but GLP-17-41 
36 also acts via the nervous system[12,9] providing an anorectic component[13]. Due to their unique properties, 42 
therapies for obesity[14] and diabetes are currently being developed based on these peptides, with promising 43 
efficacy[15] thereby highlighting their metabolic importance. Further physiological effects of these peptides are 44 
currently being uncovered, including lipolysis[16] and substrate metabolism[17-20]. 45 
Both GIP1-42 and GLP-17-36 provide a substrate for dipetidyl-petidase IV (DPP-IV) in the N-terminal 46 
regions, thought to be crucial for receptor activation[21,22]. Consequently, following cleavage, the remaining 47 
peptides GIP3-42 and GLP-19-36 are thought to be principally inactive. 48 
It is known that major macronutrients (fat and carbohydrate) stimulate GIP and GLP-1 secretion by 49 
direct contact with K- and L-cells[23]. Some recent evidence suggests that calcium could also play a crucial 50 
function. When isolated rodent intestine was perfused with increasing luminal concentrations of calcium [at 51 
humanly physiological concentrations[24]], total GIP (the accumulation of active and inactive forms) and GLP-52 
17-36 secretion was stimulated[25]. The stimulation of GIP and GLP-1 by calcium was greater in the presence of 53 
the amino acid L-phenylalanine indicating a synergistic effect. It is not currently known whether oral ingestion 54 
of calcium can augment circulating GIP and GLP-1 concentrations in humans. Due to the significance of GIP 55 
and GLP-1 in metabolic disease (whereby alterations in postprandial GIP and GLP-1 profiles are seen in type 2 56 
diabetes[26] and improvements in glycemic control following bariatric surgery parallel changes in gut 57 
peptides[27]), they may help to explain the relationship between calcium intake, obesity and type 2 diabetes. 58 
Accordingly the primary aim of the present study was to explore whether a co-ingestion of calcium 59 
with a meal augments gastrointestinal peptide concentrations in humans. Given the well-documented impact of 60 
these peptides on insulin secretion[10] and appetite[13], and some evidence that calcium can reduce energy 61 
intake[4], a secondary aim was to examine the effect of a high-calcium meal on insulinemia and appetite during 62 
the postprandial state. As both gastrointestinal peptides and calcium intake have been implicated in 63 
lipolysis[4,16] and substrate metabolism, particularly during exercise[6,20], the third objective was to assess the 64 
concomitant impact on substrate metabolism at rest and during exercise.  65 
 66 
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SUBJECTS AND METHODS 67 
Participants 68 
Young, healthy, recreationally active males were recruited between April-August 2012 from the 69 
student and staff population at Northumbria University. Participants provided written informed consent prior to 70 
the study. Eligibility criteria included, young (< 35 y), non-obese (BMI < 30 kg/m2), self-reported physically 71 
active (>30 min of structured exercise, 5 times/week) and no known metabolic or gastrointestinal diseases or 72 
food allergies. The protocols were approved by the Faculty of Health and Life Sciences Ethics Committee at 73 
Northumbria University and are therefore in accordance with the Declration of Helsinki. 74 
 75 
Preliminary measurements 76 
Prior to main trials, participants undertook preliminary tests to establish 1) the relationship between 77 
oxygen uptake and running speed on a flat treadmill using a 16-min test, and 2) their VO2peak using an 78 
incremental treadmill test whereby the gradient was increased by 1%/min to exhaustion as previously described 79 
in full detail[28]. On the same day, participants were familiarized with the visual analogue scales (VAS) to later 80 
assess subjective appetite sensations in main trials. A food frequency questionnaire, previously validated and 81 
used in similar populations[29,30], was completed to estimate habitual calcium intake. 82 
 83 
Experimental design 84 
Participants completed two trials in a randomized (randomization performed by J.T.G. using an 85 
electronic statistical package), double-blind (J.T.G. and the participants were blinded), crossover design 86 
separated by 7 d, which consisted of a control (CON) and high-calcium (CAL) trial (Figure 1). 87 
All trials were performed under similar laboratory conditions (mean ± SEM; Temperature: 21.9 ± 0.7 88 
and 21.9 ± 0.7 °C; Humidity: 39 ± 1 and 41 ± 2 %; Pressure: 1006 ± 2 and 1006 ± 4 mbar for CON and CAL 89 
trials, respectively; all P > 0.05). 90 
Food and fluid diaries were kept for the day preceding the first trial and participants were instructed to 91 
replicate this for all subsequent trials. Participants were asked to avoid all foods containing dairy in the final 92 
meal prior to trials and to abstain from alcohol, caffeine and vigorous activity (defined as any structured 93 
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exercise) for 24 h prior to trials. Participants arrived at the laboratory at Northumbria University at 0730 after a 94 
12 h fast. 95 
Arterialized venous blood samples were obtained by catheterization of a pre-heated dorsal hand vein as 96 
previously described[31]. Following baseline VAS and blood samples, breakfast was consumed and consisted 97 
of, instant oats (Oatso Simple Golden Syrup, Quaker Oats, Reading, UK), whole milk (Cravendale, Arla Foods, 98 
Denmark) and 100 ml water. This was cooked in a microwave at 1000W for 2 min to produce a porridge of 99 
semi-solid consistency. This provided 0.5 g carbohydrate/kg body mass. (energy: 1258 ± 33 kJ; 299 ± 8 kcal, 100 
protein: 11 ± 0 g, carbohydrate: 41 ± 1 g and fat: 10 ± 0 g). We chose a mixed-macronutrient meal to exploit the 101 
synergistic dose-response between amino acids and calcium on GIP and GLP-1 secretion observed in rodent 102 
intestine[25], and the glucose-dependent insulin secretions of GIP and GLP-1[10]. 103 
The CON breakfast contained 3 mg calcium/kg body mass (248 ± 7 mg). The calcium content was 104 
increased for CAL trials to 15 mg calcium/kg body mass in (1239 ± 33 mg) by using a milk-extracted calcium 105 
powder (Capolac®, Arla Foods Ingredients amba, Denmark) and was therefore a dairy source rather than 106 
supplemental calcium carbonate. The source of calcium is an important consideration regarding the 107 
physiological response[8]. The calcium powder was completely soluble in milk and the quantities used to 108 
increase the calcium content of the meal resulted in negligible increases in protein, carbohydrate and fat (all < 109 
0.5 g) and sodium, magnesium, chloride and potassium (all < 90 mg). As our working hypothesis suggests that 110 
dietary calcium influences gastrointestinal peptide secretion at the level of the gut, calcium absorption was not 111 
pertinent. The dose of calcium in CAL was chosen as an attempt to maximize the difference in the luminal 112 
concentration of calcium between CON and CAL (as a proof-of-concept), without exceeding the upper tolerable 113 
limit for adults[32].  114 
Water consumption was ad libitum during the postprandial period in the first trial and replicated for the 115 
subsequent trial. A 180-min postprandial period started upon consumption of the first mouthful of breakfast, 116 
which was consumed within 5 min. Following this, participants ran on a treadmill for 60 min at a speed 117 
designed to elicit 60% of peak oxygen uptake, considered moderate-intensity[33]. 118 
 119 
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Anthropometric measurements 120 
Body mass was determined to the nearest 0.1 kg using balance scales (Seca, Birmingham, UK) upon 121 
arrival to the laboratory, where participants wore only light clothing. Height was measured to the nearest 0.1 cm 122 
using a stadiometer (Seca, Birmingham, UK).  123 
 124 
Blood sampling and analysis 125 
Blood samples were collected at baseline, and at 15, 30, 45, 60, 90, 120, 180 min following breakfast 126 
consumption. Additional blood was sampled at 20, 25, 35 and 40 min (when it was expected that 127 
gastrointestinal peptide and insulin concentrations would peak) in order to increase resolution of the 128 
postprandial AUC. Samples were obtained whilst participants were supine to control for posture-induced 129 
changes in plasma volume. A 20 µl capillary tube was filled with whole blood to determine glucose and lactate 130 
concentrations immediately using a glucose/lactate analyzer (Biosen C_line, EKF Diagnostics, Magdeberg, 131 
Germany). 10 ml of whole blood was allowed to stand for 30 min in a non-anticoagulant tube before being 132 
centrifuged at 3000 g and 4°C for 10 min. Aliquots of serum were stored at -80°C for later determination of 133 
insulin (IBL International, Hamburg, Germany) and NEFA (WAKO Diagnostics, Richmond, VA) 134 
concentrations in duplicate. Intra-assay coefficients of variation were 3.7 % and 5.7 % for insulin and NEFA 135 
assays, respectively. 136 
Further, 4 ml EDTA tubes were filled, containing 200 kIU of aprotinin per ml of whole blood and were 137 
centrifuged immediately at 3000 g and 4°C. The supernatant was stored immediately at -80°C for later 138 
determination of GIP1-42 (Immuno-Biological Laboratories Co., Ltd, Japan) and total GLP-1 concentrations 139 
(Epitope Diagnostics, San Diego, CA). 140 
 141 
Subjective ratings 142 
Paper based, 100 mm VAS were completed at baseline, immediately following breakfast and every 30 143 
min thereafter. Questions asked were used to determine hunger, fullness, satisfaction and prospective food 144 
consumption at all time points. These were also combined to give a combined-appetite score[34] where: 145 
 146 
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Combined-appetite score = [hunger + prospective food consumption + (100 – fullness) + 147 
(100 – satisfaction)] / 4 148 
 149 
The individual components (hunger, fullness, prospective consumption and satisfaction) were still presented 150 
alongside the combined-appetite score, in order to discern the aspects of appetite that may have different 151 
determinants. Fullness, for instance, may be more closely associated with peripheral physiological changes than 152 
other aspects[35,36], which may additionally be influenced by emotional and environmental cues. 153 
Immediately following breakfast consumption a further VAS was completed, whereby questions asked 154 
were used to determine meal palatability, visual appeal, smell and taste. At the end of the trial participants were 155 
also asked to indicate whether they believed they had consumed the CON or CAL meal to assess whether the 156 
calcium could be detected. 157 
 158 
Energy expenditure and substrate oxidation 159 
Substrate metabolism was estimated with rates of oxygen consumption (VO2) and carbon dioxide 160 
production (VCO2) using stoichiometric equations, and was adjusted during exercise to account for the 161 
contribution of glycogen to metabolism[33]: 162 
 163 
Rate of lipid oxidation at rest and during exercise (g/min) = (1.695 x VO2) – (1.701 x 164 
VCO2) 165 
 166 
Rate of carbohydrate oxidation at rest (g/min) = (4.585 x VCO2) – (3.226 x VO2) 167 
 168 
Rate of carbohydrate oxidation during exercise (g/min) = (4.585 x VCO2) – (2.962 x 169 
VO2) 170 
 171 
 (VO2 and VCO2 are L/min) 172 
 173 
Energy expenditure was calculated based on lipids, glucose and glycogen providing 40.81, 15.64 and 174 
17.36 kJ/g, respectively. At rest, calculations were based on glucose providing all the carbohydrate for 175 
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metabolism, whereas during moderate intensity exercise carbohydrate oxidation is met by glucose and glycogen 176 
providing 20 and 80% contributions, respectively[33].   177 
Expired gas samples were collected using a breath-by-breath system (Metalyzer 3B, Cortex, Germany) 178 
calibrated using gases of known concentration and a 3 L syringe. For resting samples, participants wore a 179 
facemask and lay supine and after a 5-min stabilization phase, 10-min samples were obtained and averaged at 180 
baseline, and every 60 min after breakfast consumption in accordance with best practice methods[37]. Expired 181 
gas was continuously sampled throughout exercise and averaged over each 5-min period ignoring the first 5 min 182 
to allow for VO2 and VCO2 to reach a steady-state. 183 
 184 
Statistical analysis 185 
As we could not find data pertaining to either the expected effect size or the typical error of 186 
measurement for our primary outcomes of postprandial GIP1-42 or GLP-1 responses, we based our sample size 187 
on the insulin response. Using pilot data, a high-calcium meal resulted in a 12.9% increase in insulinemia 188 
(unpublished observation. Gonzalez JT, Rumbold PL, Stevenson EJ. 2012). With a typical error of 8.4% for 189 
postprandial insulinemia[38], 10 subjects should provide statistical power above 80% with an alpha level of 190 
0.05.  191 
Subjective appetite ratings and blood analyte concentrations were converted into time-averaged area 192 
under the curve (AUC) using the trapezoidal rule. As the time points after ingestion may influence the effect of 193 
a particular satiety related component (hormonal, metabolic, physical or cognitive[39]) the postprandial period 194 
was split into 0-60, 0-120 and 0-180 min.  195 
Data were tested for normal distribution using the Anderson-Darling normality test and data not 196 
displaying normal distribution were log-transformed prior to statistical analysis.  197 
Paired t-tests were used to determine differences at baseline, and differences in postprandial AUCs between 198 
trials. 199 
To determine whether habitual calcium intake influenced the postprandial responses to calcium co-200 
ingestion, pearson product-moment correlation coefficients were used to determine relationships between 201 
habitual calcium intake and the change in postprandial AUC of each of the variables. 202 
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Statistical significance was set at P < 0.05. All results are presented as mean ± SEM unless stated 203 
otherwise. 204 
 205 
RESULTS 206 
All participants completed all trials (n = 10), however due to difficulties with blood collection in one 207 
participant, data for GIP1-42, GLP-1 and NEFA are presented from 9 participants. The participants age, height, 208 
body mass, BMI, peak oxygen uptake and habitual calcium intake were (mean ± SD) 25 ± 3 y, 178.3 ± 4.9 cm, 209 
82.6 ± 6.9 kg, 26.0 ± 2.1 kg/m2, 53.1 ± 4.1 ml/kg/min and 1084 ± 544 mg/d. 210 
 211 
Plasma GIP1-42 and GLP-1 and serum insulin 212 
No significant differences were observed for plasma GIP1-42 or GLP-1, or serum insulin concentrations 213 
at baseline (P > 0.05). 214 
Postprandial GIP1-42 rose to a peak concentration of 27.5 ± 7.0 pmol/L in the CON trial and a 215 
significantly greater 47.7 ± 7.0 pmol/L in the CAL trial (P = 0.028; Figure 2A). The GIP1-42 postprandial AUC 216 
for 60, 120 and 180 min were 60, 47 and 43 % greater in the CAL trial, compared to CON, respectively (Table 217 
1; all P < 0.05). 218 
GLP-1 rose following breakfast consumption to peak concentrations of 5.2 ± 1.3 and 5.9 ± 1.3 pmol/L 219 
in CON and CAL trials, respectively (P > 0.05; Figure 2B). The GLP-1 AUC for 120 min post-breakfast was 22 220 
% greater in CAL vs. CON (Table 1; P = 0.047).  221 
Peak insulin concentrations tended to be greater following CAL vs. CON (445 ± 59 vs. 547 ± 72 222 
pmol/L; P = 0.063; Figure 2C).  The insulin AUC for the 120 min following breakfast consumption was 19% 223 
greater with CAL vs. CON (P = 0.03; Table 1). 224 
 225 
Glucose, lactate and NEFA 226 
There was no significant difference between trials in glucose or lactate or NEFA concentrations at 227 
baseline (P > 0.05). 228 
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No significant differences were detected for the glucose AUC (Figure 3A; Table 1), however, the 229 
lactate AUC for the first 60 min after meal consumption was significantly greater in CAL vs. CON (Figure 3B; 230 
Table 1; P < 0.036).  231 
The AUC for NEFA were not significantly different between trials (Table 1). NEFA concentrations 232 
were maximally suppressed at ~30 min following breakfast consumption to 0.08 ± 0.01 and 0.08 ± 0.00 mmol/L 233 
before rising to 0.29 ± 0.05 and 0.33 ± 0.06 mmol/L at the end of the postprandial period in the CON and CAL 234 
trials, respectively. As such NEFA concentrations were virtually back to baseline values at the onset of exercise 235 
(Figure 3C). 236 
 237 
Subjective ratings  238 
The visual appeal (CON: 54 ± 7, CAL: 59 ± 7), smell (CON: 71 ± 5, CAL: 76 ± 3), taste (CON: 66 ± 6, 239 
CAL: 66 ± 7), and palatability (CON: 65 ± 7, CAL: 71 ± 7) of the breakfasts were not significantly different (all 240 
P > 0.05). Additionally, participants guessed the correct breakfast administered on 7 out of 20 occasions, which 241 
is below the 50% considered as random chance. 242 
There were no significant differences in any appetite ratings at baseline (all P > 0.05). The satisfaction 243 
AUC for the first hour following breakfast consumption was 5 mm (10%) greater in the CAL trial compared to 244 
CON (P = 0.036).  245 
The combined-appetite AUC for the first hour following consumption was 5 mm (12%) lower in the 246 
CAL trial compared to CON (P = 0.034; Table 2; Figure 4).  247 
 248 
Energy expenditure and substrate utilisation 249 
There was no difference in lipid oxidation, carbohydrate oxidation or energy expenditure at baseline 250 
(all P > 0.05). There was also no interaction effect for either lipid oxidation, carbohydrate oxidation or energy 251 
expenditure (all P > 0.05). Neither postprandial nor exercise substrate oxidation differed between trials (Table 3; 252 
all P > 0.05).  253 
 254 
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Correlations between variables 255 
 There were no significant relationships between habitual calcium intake and the change in the 256 
postprandial AUC of GIP1-42, GLP-1, insulin or subjective appetite sensations in response to calcium co-257 
ingestion (all P > 0.05). 258 
 259 
DISCUSSION 260 
The primary finding from this study is that calcium co-ingestion potentiates postprandial plasma 261 
glucose-dependent insulinotropic peptide1-42 and glucagon-like peptide-1 concentrations in humans. 262 
Postprandial insulinemia and satiety were also increased with high-calcium ingestion. Substrate metabolism on 263 
the other hand, was unaffected by the calcium content of the meal. 264 
High luminal calcium concentrations stimulate the secretion of GIP and GLP-17-36 by isolated rat 265 
intestine[25], probably acting via the calcium sensing receptor. Thus, we hypothesized that an increase in the 266 
calcium content of a meal would increase the calcium concentration that the K- and L-cells are exposed to, and 267 
thus potentiate postprandial GIP and GLP-1 concentrations. This is the first study in humans to show that 268 
increasing the calcium content of a meal (from ~250 mg to ~1240 mg) amplifies the 2 h postprandial responses 269 
of GIP1-42 and total GLP-1 (by 47% and 22%, respectively). Although we could not confirm that we were able to 270 
increase the calcium concentration in the intestine, this is a likely mechanism for the responses observed.  271 
Lending support to this thesis, GIP1-42 concentrations were potentiated to a greater extent, and the 272 
enhancement was initiated more rapidly, than GLP-1 concentrations [GIP is secreted primarily from the more 273 
proximal duodenum[40], compared to the more distal jejunum and ileum for GLP-1[40] and postprandially, the 274 
duodenum is exposed to a higher concentration of calcium than the ileum[24]]. 275 
A second potential mechanism could be that decreased dietary fat absorption[7] resulted in a greater 276 
luminal fat content in the distal small intestine, thereby stimulating GLP-1 secretion in the later postprandial 277 
period, though this is does not explain the rapid changes in GIP1-42 concentrations. Calcium can also delay 278 
gastric emptying[41], and delayed gastric emptying can influence the gut peptide response[42]. However, it is 279 
just as plausible that the calcium induced increase in GLP-1, could drive the gastric emptying response[17] and 280 
hence, the direction of causality is currently unclear. 281 
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To the best of our knowledge, only one other study has determined GLP-1 responses to acute calcium 282 
ingestion[8], and found no significant effect on the postprandial AUC (GLP-1 was however, higher at 60 min 283 
following consumption of calcium carbonate). Although the large energy load (50% of total daily energy intake) 284 
provided, could have produced such a large hormonal perturbation that more subtle effects were masked. 285 
Others, using a smaller energy load determined insulin concentrations and appetite sensations following high-286 
calcium meals[4,43], although by sampling at an hourly rate, the transient effects that are reported in the present 287 
study would have been missed. 288 
CAL also increased insulinemia and influenced subjective appetite ratings in the postprandial period. It 289 
may be that increased GIP1-42 and GLP-1 concentrations are, in part, responsible for this. Both peptides potently 290 
stimulate insulin secretion when blood glucose concentrations are elevated[10]. The transient period with which 291 
insulin concentrations were potentiated imply that this is a glucose-dependent effect, as the amplification is only 292 
present when blood glucose concentrations were also above fasting values. 293 
The lower combined-appetite score with CAL was a relatively small effect and short-lived. Moreover, 294 
the impact of these findings on subsequent energy intake should be interpreted with caution, as energy intake is 295 
determined primarily by the portion size served[39] in the “real-world” setting (ie. individuals consume most of 296 
what they are served, most of the time, regardless of appetite sensations or hormonal profile). Nonetheless, self-297 
served portion size is influenced by the previous satiety experienced by food consumption[44]. Hence, an 298 
increase in satiety (decreased appetite) could have a modest effect on long-term energy balance. Moreover, a 299 
~16% reduction in 24-h energy intake has been reported after a high-calcium meal[4].  300 
It cannot be proved that the transient reduction in combined-appetite sensations with CAL was due to 301 
the changes in GLP-1 and insulin reported, particularly as other hormones, known to be influenced by calcium 302 
ingestion (such as calcitonin), are anorectic[45]. However, as serum calcitonin peaks at ~180 min following 303 
calcium ingestion[46], at which point appetite was similar between trials, it is unlikely to be a factor in the 304 
present study. In contrast, the time-course of gastrointestinal peptide, insulin and appetite responses all appear to 305 
be similar.  306 
Acute insulin administration suppresses food intake in rodents[47], and is strongly associated with 307 
postprandial fullness sensations in humans[48,35]. In addition, GLP-17-36 infusion dose-dependently reduces 308 
appetite and food intake in humans[13]. Hence, insulin and GLP-1 both affect appetite directly (with GIP 309 
providing an indirect influence through insulin). The simultaneous effects, combined with the evidence from 310 
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infusion studies makes it tempting to speculate that these responses are linked, but this needs clarifying with 311 
future work.  312 
We chose to measure total GLP-1 rather than the “active” GLP-17-36. In humans, all the GLP-1 secreted 313 
is in the 7-36 form[49]. Before entering the systemic circulation, approximately 50% has been cleaved [9] 314 
producing GLP-19-36, believed to be physiologically inactive [but may act through receptors other than the 315 
classical GLP-1 receptor[50]]. However it is thought that GLP-1 can act centrally [acting on the hypothalamus 316 
via sensory afferent neurons and subsequently neurons of the solitary tract nucleus [51]] prior to entering the 317 
circulation, and potentiate insulinemia through neural and direct pancreatic β-cell stimulation[12,52]. Thus, 318 
measuring the active form and its metabolite provides an indication of total GLP-1 secretion, which is likely to 319 
have physiological effects before entering the circulation[9].  320 
Contrary to GLP-1, GIP is thought to act only through its receptor as GIP1-42[50] and as such, we chose 321 
to measure GIP1-42 to reflect the tissue exposure to the active peptide. GIP1-42 is not believed to have a direct 322 
impact on appetite, but could have an influence through GLP-1 and insulin secretion.  323 
In spite of a 20% increase in insulinemia, we saw no difference in glycemia or serum NEFA 324 
availability between trials. The reason for this is likely due to the glucagonotropic effect of GIP[10,53,54], 325 
thereby maintaining the glucagon/insulin ratio. Furthermore, the greater insulinemia was transitory in nature 326 
(with the greatest differences seen from 20-60 min postprandially), and this not of sufficient duration to 327 
influence glucose uptake. 328 
The similar lipid oxidation between trials support the findings of some[55,56] but not others[4,57]. 329 
When lipid oxidation has been stimulated by a high-calcium meal, this has occurred with simultaneous 330 
enhanced NEFA availability[57,4]. We did not observe a difference in NEFA availability, and NEFA 331 
concentrations had returned to almost fasting values prior to exercise. Therefore the meal-induced suppression 332 
of NEFA concentrations[58] was not overriding the ability to detect a difference in either NEFA availability or 333 
lipid oxidation. The discrepancy between studies may, in part, be accounted for by the populations used (healthy 334 
BMI vs. overweight/obese) as metabolic functions of GLP-1, are more apparent in obesity[17,18]. 335 
Blood lactate concentrations were elevated with calcium co-ingestion for the first 60 min following 336 
ingestion, which could indicate a greater reliance on carbohydrate oxidation. An explanation for this is not 337 
readily forthcoming, particularly given that DPP-IV inhibition (which elevates GIP1-42 and GLP-17-36 338 
concentrations) decreases muscle dialysate lactate concentration[19], although the 120 and 180 min postprandial 339 
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AUC were similar between trials. 340 
The dose of calcium in the CAL trial was within the upper tolerable limit for adults[32], although 341 
would unlikely be consumed in a single-meal under normal-circumstances (this dose equates to almost 1L of 342 
whole milk). This may in part, explain the discrepancy between the present study and that of Lorenzen et al.[8] 343 
as the high calcium dose with a small meal in the present study would result in a higher concentration of 344 
calcium in the gastrointestinal tract, compared to a similar or smaller dose of calcium diluted in a large meal[8]. 345 
Furthermore the findings of this study should be placed into the context of clinical relevance. On average, the 346 
participants had an adequate habitual calcium intake and a normal BMI. Calcium supplementation at high levels 347 
has been implicated in renal stone formation[59] and cardiovascular disease mortality[60]. Although neither of 348 
these are without controversy[61,62]. Insulin per se can cause atherogenesis and insulin resistance, which in 349 
turn are strongly associated with cardiovascular disease (reviewed in[63]). Thus raising the question of the 350 
cost/benefit of the insulin and gut peptide responses seen in the present study, particularly if this is also seen in 351 
high-risk populations. 352 
A limitation with this study is the relatively small sample size, and thus the relevance to a wider 353 
population needs evaluating.  This study does however, provide a proof-of-principle that calcium ingestion 354 
influences postprandial insulin and gastrointestinal peptide concentrations and appetite sensations, and further 355 
work should aim to establish the dose-response of this relationship. 356 
It is noteworthy that apart from the calcium content, the test meals were identical in nutritional 357 
composition and similar in palatability, visual appeal, taste and smell. Participants were also unable to detect a 358 
difference between the test meals and as such the impact of palatability on postprandial appetite[64] or 359 
insulinemia[65] can be eliminated. 360 
In conclusion, increasing the calcium content of a meal augments postprandial circulating GIP1-42 and 361 
total GLP-1 concentrations in humans. The high-calcium meals also resulted in greater insulinemia and satiety. 362 
Substrate metabolism, however, was not affect by calcium co-ingestion. 363 
 364 
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TABLE 1 
 Postprandial responses of circulating parameters to calcium co-ingestion in young healthy males 
  
Data are expressed as means ± SEM. Data not normally distributed as assessed by the Anderson-Darling 
normality test were log-transformed for statistical analysis. CON, control; CAL, calcium co-ingestion; GIP1-
42, glucose-dependent insulinotropic peptide1-42; GLP-1, glucagon-like peptide-1; NEFA, non-esterified 
fatty acid. *Significant difference between CAL vs. CON, P < 0.05 assessed by paired t-tests. 
  
 Time-averaged postprandial area under the curve 
 0-60 min  0-120 min  0-180 min 
Variable CON CAL CON CAL CON CAL 
Plasma GIP1-42 
(pmol/L) 
21 ± 6 33* ± 6 18 ± 5 25* ± 5 13 ± 3 18* ± 3 
Plasma GLP-1 
(pmol/L) 
3.18 ± 0.75 3.96 ± 1.17 2.72 ± 0.62 3.71* ± 1.26 2.43 ± 0.56 3.41 ± 1.24 
Serum insulin  
(pmol/L) 
235 ± 24 278 ± 27 161 ± 12 192* ± 15 133 ± 10 161 ± 13 
Blood glucose 
(mmol/L) 
5.6 ± 0.2 5.7 ± 0.2 5.1 ± 0.1 5.2 ± 0.1 4.9 ± 0.1 5.0 ± 0.1 
Blood lactate 
(mmol/L) 
0.73 ± 0.05 0.90* ± 0.06  0.75 ± 0.05 0.86 ± 0.07  0.73 ± 0.06 0.79 ± 0.06 
Serum NEFA 
(mmol/L) 
0.18 ± 0.02 0.21 ± 0.03  0.15 ± 0.02 0.16 ± 0.02  0.17 ± 0.02 0.19 ± 0.02 
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TABLE 2 
Postprandial subjective appetite responses to calcium co-ingestion in young healthy males 
 
 
 
 
 
 
 
 
  
 
Data are expressed as means ± SEM. CON, control; CAL, calcium co-ingestion. *Significant difference 
between CAL vs. CON, P < 0.05 assessed by paired t-tests. 
 
 
 
 
 
 
 
 
 
 
 
  
 Time-averaged postprandial area under the curve 
 0-60 min  0-120 min 
 
0-180 min 
Variable CON CAL  CON CAL CON CAL 
Hunger 40 ± 6 36 ± 6  43 ± 6 41 ± 6 47 ± 6 46 ± 5 
Fullness 56 ± 7 60 ± 7  51 ± 6 53 ± 6  45 ± 6 49 ± 6 
Satisfaction 54 ± 6 59* ± 6  50 ± 6 52 ± 6  45 ± 6 47 ± 6 
Prospective consumption 47 ± 7 40 ± 7  50 ± 7 47 ± 6  54 ± 6 52 ± 6 
Combined-appetite 44 ± 6 39* ± 6  48 ± 6 46 ± 6  53 ± 6 51 ± 6 
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TABLE 3 
 
Substrate oxidation and energy expenditure during the postprandial and exercise periods 
 
 
 
 
 
 
 
 
 
 
Data are expressed as means ± SEM. CON, control; CAL, calcium co-ingestion; CHO, carbohydrate; RER, 
respiratory exchange ratio. No significant differences were detected between trials. 
 Postprandial period 
(0-180 min) 
 Exercise period 
(180-240 min) 
Variable CON CAL  CON CAL 
Lipid oxidation (g) 12.2 ± 0.6 13.1 ± 0.5  27.3 ± 1.1 29.1 ± 1.0 
CHO oxidation (g) 42.7 ± 1.5 38.6 ± 1.3  129.0 ± 3.4 121.2 ± 4.0 
Energy expenditure (kJ) 1168 ± 17 1139 ± 20  3135 ± 34 3085 ± 33 
RER (au) 0.870 ± 0.01 0.856 ± 0.004  0.894 ± 0.004 0.883 ± 0.005 
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Figure Legends: 
 
FIGURE 1. Schematic representation of the main trials. 
 
FIGURE 2. Plasma GIP1-42 (A) and GLP-1 (B), and serum insulin (C) concentrations following consumption 
of a control (CON; 3 mg calcium/kg body mass) or high-calcium (CAL; 15 mg calcium/kg body mass) meal. 
Data are means ± SEM, n = 9. GIP1-42, glucose-dependent insulinotropic peptide1-42; GLP-1, glucagon-like 
peptide-1; grey rectangle represents the exercise period.  
 
FIGURE 3. Blood glucose (A), lactate (B), and serum NEFA (C) concentrations following consumption of a 
control (CON; 3 mg calcium/kg body mass) or high-calcium (CAL; 15 mg calcium/kg body mass) meal. 
Data are means ± SEM, n = 10 for glucose and lactate and n = 9 for NEFA. Grey rectangle represents the 
exercise period. 
 
FIGURE 4. Combined-appetite scores following consumption of a control (CON; 3 mg calcium/kg body 
mass) or high-calcium (CAL; 15 mg calcium/kg body mass) meal. Data are mean ± SEM, n = 10. Grey 
rectangle represents the exercise period. 
 
